
11 Jan 2019 Research
Leukaemia: Investigating stem cells to prevent cancer
What is this research looking at?
The development of effective treatments to prevent and eradicate leukaemia requires a better understanding of the mechanisms behind malignant (harmful) transformation and disease persistence during therapy.
Importantly, leukaemia development is associated with the acquisition of abnormal metabolic features, making cancer metabolism an attractive target for new therapeutic strategies.
Metabolism is closely associated to cell functions in normal and abnormal (malignant) tissues. By measuring metabolic heterogeneity in normal tissue (haemopoietic stem cells) and in cancer (leukaemia), I will determine whether distinct cell metabolic states are functionally connected to their potential for malignant transformation and therapy resistance.
I will test if malignant transformation and therapy resistance can be prevented or attenuated by targeting their metabolic dependencies. Results from the proposed research may lead to the development of new strategies for leukaemia eradication and prevention.
What could this mean for people with leukaemia?
This project investigates the metabolic features of stem cells in a bid to find out how to prevent them turning cancerous and to reduce resistance to treatment – this may lead to the development of new strategies for leukaemia eradication and prevention.
Related posts
8 July 2025
The first ever leukaemia-dedicated pathway to improve diagnosis, treatment and care
The Best Practice Timed Pathway We’re delighted to share that Leukaemia UK, in partnership with Lymphoma Action and Myeloma UK, is working with the NHS England Cancer programme team to…
4 April 2022
Leukaemia UK launches search for five new talented Trustees
We are looking for a talented and diverse set of Trustees to join our Board, and help guide the charity as we embark on an ambitious new strategy to accelerate progress in leukaemia research to stop leukaemia devastating lives.
4 April 2023
£200 grants for people affected by leukaemia once again available
Leukaemia UK and Leukaemia Care have this month relaunched the ‘Cost of Living Fund’, providing financial grants of £200 to patients with leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs),…
10 November 2021
An urgent call from One Cancer Voice group of cancer charities for the Comprehensive Spending Review to deliver Government commitments to improve cancer survival & care
Leukaemia UK has joined with 50 other cancer charities in writing to the Prime Minister, Chancellor of the Exchequer and Secretary of State for Health and Social Care. We are calling on the Government to urgently deliver on commitments to improve cancer survival and care in the forthcoming Spending Review.